Seattle Genetics announces approval of TUKYSA by the U.S. Food and Drug Administration (FDA).

TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. We look forward to sharing the efficacy and safety data from the HER2CLIMB trial as you consider adding TUKYSA to your formularies.

  51144-002-60   150 mg 60 tablets per bottle
  51144-001-60   50 mg 60 tablets per bottle

Please click here for Full Prescribing Information.

No comments have been posted yet.